Loading…
Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling
We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and...
Saved in:
Published in: | Journal of medical virology 2018-07, Vol.90 (7), p.1257-1263 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573 |
---|---|
cites | cdi_FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573 |
container_end_page | 1263 |
container_issue | 7 |
container_start_page | 1257 |
container_title | Journal of medical virology |
container_volume | 90 |
creator | Marascio, Nadia Pavia, Grazia Romeo, Isabella Talarico, Carmine Di Salvo, Sebastiano Reale, Mariaconcetta Marano, Vito Barreca, Giorgio Settimo Fabiani, Fernanda Perrotti, Nicola De Siena, Massimo Giancotti, Francesca Gravina, Tiziana Alcaro, Stefano Artese, Anna Torti, Carlo Liberto, Maria Carla Focà, Alfredo |
description | We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein. |
doi_str_mv | 10.1002/jmv.25073 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2018662766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2018662766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573</originalsourceid><addsrcrecordid>eNp1kc1u1DAQgK0K1C6FAy-ARuJSDmnHdmIn3FYtUGgBqT9cIyexWa_sdWpvWnKDN-AZeRKy3cIBCV_Gh0-fNPMR8pziIUVkR0t_e8gKlHyHzChWIqtQ0kdkhjQXmRC02CNPUloiYlkxtkv2WFXIAgXOyI8Lrdyv7z-dNRr4CawXOqp-BKOsG6J-DfOVcmOyCYKBT5fFHCp-ChfzS-jdkIBiCWfQBzf6EPuFTR7sCtrge6e_wZ1dLyD4xq5VurURmhF8cLodnIrTr9POrr4-JY-Nckk_e5j75Prtm6vj0-z887v3x_PzrOUF51nZ0TJXbHo0R6mkNJIx1alWFI0xgndclorRBptcMsFpPq3IWmEqJVSbF5Lvk4Ott4_hZtBpXXubWu2cWukwpJohLYVgUogJffkPugxDnA6xoXKZcyzpRvhqS7UxpBS1qftovYpjTbHedKmnLvV9l4l98WAcGq-7v-SfEBNwtAXurNPj_031h49ftsrfg4eVjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2047430817</pqid></control><display><type>article</type><title>Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Marascio, Nadia ; Pavia, Grazia ; Romeo, Isabella ; Talarico, Carmine ; Di Salvo, Sebastiano ; Reale, Mariaconcetta ; Marano, Vito ; Barreca, Giorgio Settimo ; Fabiani, Fernanda ; Perrotti, Nicola ; De Siena, Massimo ; Giancotti, Francesca ; Gravina, Tiziana ; Alcaro, Stefano ; Artese, Anna ; Torti, Carlo ; Liberto, Maria Carla ; Focà, Alfredo</creator><creatorcontrib>Marascio, Nadia ; Pavia, Grazia ; Romeo, Isabella ; Talarico, Carmine ; Di Salvo, Sebastiano ; Reale, Mariaconcetta ; Marano, Vito ; Barreca, Giorgio Settimo ; Fabiani, Fernanda ; Perrotti, Nicola ; De Siena, Massimo ; Giancotti, Francesca ; Gravina, Tiziana ; Alcaro, Stefano ; Artese, Anna ; Torti, Carlo ; Liberto, Maria Carla ; Focà, Alfredo</creatorcontrib><description>We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.25073</identifier><identifier>PMID: 29575060</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Aged ; Amino acid sequence ; Anilides - pharmacology ; Antiviral Agents - pharmacology ; Carbamates - pharmacology ; computational analysis ; Computer applications ; Computer simulation ; docking ; Dynamic stability ; Failure analysis ; HCV phosphoprotein ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Humans ; Male ; Models, Molecular ; Molecular chains ; Molecular dynamics ; Molecular Dynamics Simulation ; molecular dynamics simulations ; Molecular modelling ; Molecular structure ; Mutation, Missense ; Polymorphism ; Polymorphism, Genetic ; Proline ; Proteins ; Recurrence ; resistance‐associated substitutions ; Ribavirin ; Ritonavir ; Therapy ; Treatment Failure ; Valine ; Viral Nonstructural Proteins - chemistry ; Viral Nonstructural Proteins - genetics ; Virology</subject><ispartof>Journal of medical virology, 2018-07, Vol.90 (7), p.1257-1263</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573</citedby><cites>FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573</cites><orcidid>0000-0003-0880-8955</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29575060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marascio, Nadia</creatorcontrib><creatorcontrib>Pavia, Grazia</creatorcontrib><creatorcontrib>Romeo, Isabella</creatorcontrib><creatorcontrib>Talarico, Carmine</creatorcontrib><creatorcontrib>Di Salvo, Sebastiano</creatorcontrib><creatorcontrib>Reale, Mariaconcetta</creatorcontrib><creatorcontrib>Marano, Vito</creatorcontrib><creatorcontrib>Barreca, Giorgio Settimo</creatorcontrib><creatorcontrib>Fabiani, Fernanda</creatorcontrib><creatorcontrib>Perrotti, Nicola</creatorcontrib><creatorcontrib>De Siena, Massimo</creatorcontrib><creatorcontrib>Giancotti, Francesca</creatorcontrib><creatorcontrib>Gravina, Tiziana</creatorcontrib><creatorcontrib>Alcaro, Stefano</creatorcontrib><creatorcontrib>Artese, Anna</creatorcontrib><creatorcontrib>Torti, Carlo</creatorcontrib><creatorcontrib>Liberto, Maria Carla</creatorcontrib><creatorcontrib>Focà, Alfredo</creatorcontrib><title>Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.</description><subject>Aged</subject><subject>Amino acid sequence</subject><subject>Anilides - pharmacology</subject><subject>Antiviral Agents - pharmacology</subject><subject>Carbamates - pharmacology</subject><subject>computational analysis</subject><subject>Computer applications</subject><subject>Computer simulation</subject><subject>docking</subject><subject>Dynamic stability</subject><subject>Failure analysis</subject><subject>HCV phosphoprotein</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Male</subject><subject>Models, Molecular</subject><subject>Molecular chains</subject><subject>Molecular dynamics</subject><subject>Molecular Dynamics Simulation</subject><subject>molecular dynamics simulations</subject><subject>Molecular modelling</subject><subject>Molecular structure</subject><subject>Mutation, Missense</subject><subject>Polymorphism</subject><subject>Polymorphism, Genetic</subject><subject>Proline</subject><subject>Proteins</subject><subject>Recurrence</subject><subject>resistance‐associated substitutions</subject><subject>Ribavirin</subject><subject>Ritonavir</subject><subject>Therapy</subject><subject>Treatment Failure</subject><subject>Valine</subject><subject>Viral Nonstructural Proteins - chemistry</subject><subject>Viral Nonstructural Proteins - genetics</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1DAQgK0K1C6FAy-ARuJSDmnHdmIn3FYtUGgBqT9cIyexWa_sdWpvWnKDN-AZeRKy3cIBCV_Gh0-fNPMR8pziIUVkR0t_e8gKlHyHzChWIqtQ0kdkhjQXmRC02CNPUloiYlkxtkv2WFXIAgXOyI8Lrdyv7z-dNRr4CawXOqp-BKOsG6J-DfOVcmOyCYKBT5fFHCp-ChfzS-jdkIBiCWfQBzf6EPuFTR7sCtrge6e_wZ1dLyD4xq5VurURmhF8cLodnIrTr9POrr4-JY-Nckk_e5j75Prtm6vj0-z887v3x_PzrOUF51nZ0TJXbHo0R6mkNJIx1alWFI0xgndclorRBptcMsFpPq3IWmEqJVSbF5Lvk4Ott4_hZtBpXXubWu2cWukwpJohLYVgUogJffkPugxDnA6xoXKZcyzpRvhqS7UxpBS1qftovYpjTbHedKmnLvV9l4l98WAcGq-7v-SfEBNwtAXurNPj_031h49ftsrfg4eVjw</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Marascio, Nadia</creator><creator>Pavia, Grazia</creator><creator>Romeo, Isabella</creator><creator>Talarico, Carmine</creator><creator>Di Salvo, Sebastiano</creator><creator>Reale, Mariaconcetta</creator><creator>Marano, Vito</creator><creator>Barreca, Giorgio Settimo</creator><creator>Fabiani, Fernanda</creator><creator>Perrotti, Nicola</creator><creator>De Siena, Massimo</creator><creator>Giancotti, Francesca</creator><creator>Gravina, Tiziana</creator><creator>Alcaro, Stefano</creator><creator>Artese, Anna</creator><creator>Torti, Carlo</creator><creator>Liberto, Maria Carla</creator><creator>Focà, Alfredo</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0880-8955</orcidid></search><sort><creationdate>201807</creationdate><title>Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling</title><author>Marascio, Nadia ; Pavia, Grazia ; Romeo, Isabella ; Talarico, Carmine ; Di Salvo, Sebastiano ; Reale, Mariaconcetta ; Marano, Vito ; Barreca, Giorgio Settimo ; Fabiani, Fernanda ; Perrotti, Nicola ; De Siena, Massimo ; Giancotti, Francesca ; Gravina, Tiziana ; Alcaro, Stefano ; Artese, Anna ; Torti, Carlo ; Liberto, Maria Carla ; Focà, Alfredo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Amino acid sequence</topic><topic>Anilides - pharmacology</topic><topic>Antiviral Agents - pharmacology</topic><topic>Carbamates - pharmacology</topic><topic>computational analysis</topic><topic>Computer applications</topic><topic>Computer simulation</topic><topic>docking</topic><topic>Dynamic stability</topic><topic>Failure analysis</topic><topic>HCV phosphoprotein</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Male</topic><topic>Models, Molecular</topic><topic>Molecular chains</topic><topic>Molecular dynamics</topic><topic>Molecular Dynamics Simulation</topic><topic>molecular dynamics simulations</topic><topic>Molecular modelling</topic><topic>Molecular structure</topic><topic>Mutation, Missense</topic><topic>Polymorphism</topic><topic>Polymorphism, Genetic</topic><topic>Proline</topic><topic>Proteins</topic><topic>Recurrence</topic><topic>resistance‐associated substitutions</topic><topic>Ribavirin</topic><topic>Ritonavir</topic><topic>Therapy</topic><topic>Treatment Failure</topic><topic>Valine</topic><topic>Viral Nonstructural Proteins - chemistry</topic><topic>Viral Nonstructural Proteins - genetics</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marascio, Nadia</creatorcontrib><creatorcontrib>Pavia, Grazia</creatorcontrib><creatorcontrib>Romeo, Isabella</creatorcontrib><creatorcontrib>Talarico, Carmine</creatorcontrib><creatorcontrib>Di Salvo, Sebastiano</creatorcontrib><creatorcontrib>Reale, Mariaconcetta</creatorcontrib><creatorcontrib>Marano, Vito</creatorcontrib><creatorcontrib>Barreca, Giorgio Settimo</creatorcontrib><creatorcontrib>Fabiani, Fernanda</creatorcontrib><creatorcontrib>Perrotti, Nicola</creatorcontrib><creatorcontrib>De Siena, Massimo</creatorcontrib><creatorcontrib>Giancotti, Francesca</creatorcontrib><creatorcontrib>Gravina, Tiziana</creatorcontrib><creatorcontrib>Alcaro, Stefano</creatorcontrib><creatorcontrib>Artese, Anna</creatorcontrib><creatorcontrib>Torti, Carlo</creatorcontrib><creatorcontrib>Liberto, Maria Carla</creatorcontrib><creatorcontrib>Focà, Alfredo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marascio, Nadia</au><au>Pavia, Grazia</au><au>Romeo, Isabella</au><au>Talarico, Carmine</au><au>Di Salvo, Sebastiano</au><au>Reale, Mariaconcetta</au><au>Marano, Vito</au><au>Barreca, Giorgio Settimo</au><au>Fabiani, Fernanda</au><au>Perrotti, Nicola</au><au>De Siena, Massimo</au><au>Giancotti, Francesca</au><au>Gravina, Tiziana</au><au>Alcaro, Stefano</au><au>Artese, Anna</au><au>Torti, Carlo</au><au>Liberto, Maria Carla</au><au>Focà, Alfredo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2018-07</date><risdate>2018</risdate><volume>90</volume><issue>7</issue><spage>1257</spage><epage>1263</epage><pages>1257-1263</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29575060</pmid><doi>10.1002/jmv.25073</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0880-8955</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0146-6615 |
ispartof | Journal of medical virology, 2018-07, Vol.90 (7), p.1257-1263 |
issn | 0146-6615 1096-9071 |
language | eng |
recordid | cdi_proquest_miscellaneous_2018662766 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Aged Amino acid sequence Anilides - pharmacology Antiviral Agents - pharmacology Carbamates - pharmacology computational analysis Computer applications Computer simulation docking Dynamic stability Failure analysis HCV phosphoprotein Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Male Models, Molecular Molecular chains Molecular dynamics Molecular Dynamics Simulation molecular dynamics simulations Molecular modelling Molecular structure Mutation, Missense Polymorphism Polymorphism, Genetic Proline Proteins Recurrence resistance‐associated substitutions Ribavirin Ritonavir Therapy Treatment Failure Valine Viral Nonstructural Proteins - chemistry Viral Nonstructural Proteins - genetics Virology |
title | Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T13%3A04%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90life%203D%20therapy%20failure:%20Analysis%20of%20NS5A%2093H%20RAS%20plus%20108%20K%20polymorphism%20in%20complex%20with%20ombitasvir%20by%20molecular%20modeling&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Marascio,%20Nadia&rft.date=2018-07&rft.volume=90&rft.issue=7&rft.spage=1257&rft.epage=1263&rft.pages=1257-1263&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.25073&rft_dat=%3Cproquest_cross%3E2018662766%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2047430817&rft_id=info:pmid/29575060&rfr_iscdi=true |